Custom Prefilled Syringe Assembly Manufacturer for Insulin

Inside Wuxi NEST Biotechnology’s Approach to Custom Prefilled Syringe Assembly for Insulin Therapies

For pharmaceutical companies developing insulin, GLP-1, or FSH therapies, selecting a manufacturing partner for prefilled syringe assembly is a decision that touches patient safety, regulatory timelines, and long-term supply reliability. Wuxi NEST Biotechnology Co., Ltd., operating under the brand NEST, has built its business specifically around this challenge, positioning itself as a one-stop provider of pharmaceutical packaging materials and drug delivery technologies focused on injection and inhalation methods.

Why the Market Needs a Dedicated Combination-Product Partner

NEST’s corporate positioning is grounded in a clear industry pain point: the rising incidence of chronic diseases has increased demand for precision dosing and self-administration solutions that reduce clinical workload, minimize needle-stick injuries, and prevent medication waste. Insulin manufacturers, in particular, require packaging and delivery components that are both clinically dependable and easy to scale across global markets. Founded in 2018 and headquartered in Wuxi, Jiangsu, China, NEST entered the pharmaceutical packaging sector with this specific gap in mind, later expanding its business coverage to the United States, the Netherlands, the United Arab Emirates, Japan, and Turkey.

Core Differentiators Behind the Prefilled Syringe Assembly Line

What separates NEST from a typical component supplier is its full in-house industry chain, spanning independent mold design and R&D, automated mass production, and global logistics. This vertical integration is paired with Freedom to Operate (FTO) analysis across major global markets—China, the US, the UK, and Europe—to help mitigate patent risks for clients bringing new drug-device combinations to market. NEST describes its value proposition as empowering global advancement of drug-device combinations through smarter, more targeted treatment and precision dosing, a principle that directly informs the design of its COP/COC Prefilled Syringe Assembly and related primary packaging products.

Primary Packaging Line: The Technical Foundation

The company’s Primary Packaging Line includes the COP/COC Prefilled Syringe Assembly alongside two closely related product families that illustrate the underlying material science and process controls applied across the portfolio.

RTU Cartridges, positioned as next-generation parenteral packaging, are constructed from borosilicate glass and treated with NEST’s proprietary cross-linked siliconization technology, which is engineered for stable gliding performance in syringes and cartridges. These cartridges are available in 1.5mL, 2.0mL, and 3.0mL formats, giving formulation teams flexibility in dose volume planning.

COP/COC Prefillable Vial (AccureVial®) is offered as a high-quality alternative to borosilicate glass for sensitive biologics. Its differentiated value rests on two pillars: low protein adsorption for stability, and a shatter-resistant COP material for durability. The vial’s technical profile includes a temperature tolerance range of -196°C to 121°C, which supports demanding cold-chain and sterilization requirements common in biologic and insulin formulations.

The COP/COC Prefilled Syringe Assembly sits within this same primary packaging line, benefiting from the same material science expertise and manufacturing infrastructure that underpins the RTU Cartridges and AccureVial® products, giving insulin manufacturers a packaging option built on validated glass-alternative technology and siliconization performance already proven across NEST’s cartridge and vial lines.

Manufacturing Scale and Quality Infrastructure

NEST’s production capacity is supported by a 76-person specialized quality team and a 50-person mold maintenance team. Its facilities include 10,600 m² of Class 100,000 cleanrooms, 3,600 m² of Class 10,000 cleanrooms, and a dedicated 2,300 m² pen injector workshop. On the technical side, the company applies 100% multi-angle CCD camera inspection and offers moist heat sterilization capabilities at SAL 10⁻⁶, reflecting a sterility assurance level commonly required for injectable drug packaging. NEST has been identified as a provider of moist heat sterilized cartridges in China, a milestone tied to its broader push into higher-assurance sterilization processes.

Since its 2018 entry into pharmaceutical packaging, NEST has built out this capability progressively—registering its Disposable Intranasal Atomization Device in 2019, and securing multiple international certifications and licenses for its pen injector and syringe product lines between 2023 and 2025, including FDA 510(k), Canada MDL, and China CDE approvals.

Certifications Supporting Regulatory Confidence

For pharmaceutical buyers evaluating a custom manufacturer, documented certification is a practical requirement rather than a marketing detail. NEST holds ISO 9001, ISO 13485, ISO 11137, ISO 15378, and IATF 16949 certifications, along with CE MDR Certification and MDSAP Five-Country Certification covering the USA, Canada, Australia, Japan, and Brazil. Its filings include US FDA 510(k) approvals (K240961, K240774), US DMF listings (No. 40744, No. 42439, No. 40922), Canada Medical Device Licenses (No. 113733, No. 112619), and a China Class II Medical Device Certificate. These credentials are further validated through third-party certification bodies, including TÜV SÜD for ISO 9001/13485/11137, alongside the company’s FDA 510(k) and DMF filings.

Data Integrity and Compliance Across the Product Lifecycle

Beyond physical manufacturing, NEST maintains full lifecycle validation and batch traceability through batch numbers and retained samples, supporting compliance needs throughout a product’s commercial life. The company’s processes are also compliant with RoHS and REACH regulations, addressing environmental and material safety requirements that pharmaceutical and life sciences customers must satisfy when qualifying new suppliers.

Service Model and Global Delivery

NEST structures its service offering around one-stop solutions covering R&D, production, pre-sterilization, and customized assembly. This includes pre-sales customization, technical validation, automated assembly line planning, and global logistics support. The company maintains integrated warehousing across the US, Europe, and Asia to shorten lead times, with subsidiary and warehouse operations in Woodbridge, NJ and Phoenix, AZ in the United States; Hendrik-Ido-Ambacht in the Netherlands; Sharjah in the UAE; Yokohama in Japan; and Istanbul in Turkey, alongside its Wuxi headquarters and R&D base in China.

Serving a Focused Range of Industries

NEST’s customer base spans biopharmaceuticals, medical aesthetics, and life sciences, with customer types including pharmaceutical companies producing insulin, GLP-1, and FSH therapies, along with research institutions and hospitals. In one documented case, the company’s Disposable Intranasal Atomization Device was applied to a Lyophilized Live Attenuated Influenza Vaccine for intranasal vaccination, successfully stimulating a triple immune response across mucosal, humoral, and cellular pathways—an example that speaks to the breadth of NEST’s drug-device combination validation experience beyond injectable formats alone.

A Practical Path for Insulin Manufacturers

For companies seeking a custom prefilled syringe assembly manufacturer, NEST’s combination of in-house mold design, cross-linked siliconization technology, multi-country certification coverage, and globally distributed warehousing offers a structured, traceable path from formulation to finished device—pricing determined on a custom enterprise basis according to volume and customization requirements, with full lifecycle technical support and validation assistance included after delivery.

https://www.cell-nestbio.com/
NEST Biotechnology Co., Ltd.